FDA Announces the Availability of Additional Submission Tools for Cosmetic Product Facility Registration and Cosmetic Product Listing The FDA announced the availability of SPL Xforms, an SPL authoring tool for cosmetic product facility registration and cosmetic product listing. Also announced was the availability of Form FDA 5066 and Form FDA 5067 which would be mailed to the FDA upon completion. Although physical forms are available, the agency highly recommends electronic submission of registration and listing information.
The FDA has created a database to conduct a Search for Pharmaceutical Quality Documents.
DRAFT Guidance Documents Available for Comment
FDA is issuing the draft guidance to describe the Agency’s current thinking regarding its use of remote regulatory assessments in order to increase industry’s understanding of RRAs and facilitate FDA’s process for conducting RRAs. FDA has used RRAs to conduct oversight, mitigate risk, meet critical public health needs and help maximize compliance of FDA-regulated products.
Comments may be made to Docket Number FDA-2022-D-0810
This guidance discusses certain quality considerations for ophthalmic drug products (i.e., gels, ointments, creams, and liquid formulations such as solutions, suspensions, and emulsions) intended for topical delivery in and around the eye.
Submit Comments by 26 February 2024
This draft guidance provides recommendations on the procedures for applicants of abbreviated new drug applications that wish to pursue a request for reconsideration within the review discipline at the division level or original signatory authority.
Submit Comments by 11 March 2024
This draft guidance document provides the FDA’s recommendations on information to support premarket submissions for metallic coatings and/or calcium phosphate coatings on orthopedic devices. This guidance applies to metallic coatings, calcium phosphate coatings, or metallic and calcium phosphate dual coatings on orthopedic devices.
Submit Comments by 22 March 2024
This document provides guidance regarding good manufacturing practice for the manufacturing of active pharmaceutical ingredients under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.
Submit Comments by 25 March 2024
This draft guidance provides recommendations for developing a science- and risk-based strategy to help assure the potency of a human cellular therapy or gene therapy (CGT) product. A potency assurance strategy is a multifaceted approach that reduces risks to the potency of a product through manufacturing process design, manufacturing process control, material control, in-process testing, and potency lot release assays. The goal of a potency assurance strategy is to ensure that every lot of a product released will have the specific ability or capacity to achieve the intended therapeutic effect.
Submit Comments by 27 March 2024
Highlighted Guidance Documents
This guidance is intended to assist applicants and holders of an ANDA in updating their labeling following revisions to the approved labeling of a reference listed drug. This guidance provides recommendations on identifying RLD labeling updates and submitting ANDA amendments or supplements to update generic drug labeling. After it has been finalized, this guidance will replace the April 2000 guidance.
This guidance is intended to assist applicants in preparing and submitting amendments to tentatively approved abbreviated new drug applications, including requests for final approval. This guidance provides recommendations on the timing and content of amendments to tentatively approved ANDAs to facilitate submission in a timely fashion to enable final approval on the earliest date on which the ANDA may lawfully be approved based on patent and/or exclusivity protections.
This guidance document updates and clarifies the information regarding sterilization processes that the agency recommends sponsors include in 510(k)s for devices labeled as sterile. This guidance document also provides details about the pyrogenicity information that the agency recommends sponsors include in a 510(k) submission. For the current edition of the FDA-recognized standards referenced in this document, see the FDA Recognized Consensus Standards Database Web site at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm.
All Guidance Documents can be searched on the FDA’s website.
- FR Vol. 89, No. 17 (4950), Voluntary Quality Management Maturity Prototype Assessment Protocol Evaluation Program
- FR Vol. 89, No. 17 (4952), Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability
- FR Vol. 89, No. 18 (5244), Conducting Remote Regulatory Assessments-Questions and Answers; Revised Draft Guidance for Industry; Availability
- A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Symposium
Dates: February 13 – 15, 2024
Day1: Tue, Feb 13 8:30 AM – 3:35 PM ET
Day2: Wed, Feb 14 8:30 AM – 3:50 PM ET
Day3: Thu, Feb 15 8:30 AM – 4:50 PM ET
- Joint US FDA – Health Canada ICH Public Meeting
Date: February 22, 2024
Time: 11:00 AM – 3:00 PM ET
- Expanding Generic Drug Access Through International Engagements
Date: February 28, 2024
Time: 9:00 AM – 11:30 AM ET
- Public meeting: FDA Rare Disease Day 2024
Date: March 1, 2024
Time: 9:00 AM – 4:30 PM ET
- Integrated Safety Analyses in Drug Marketing Applications: Avoiding Common Mistakes
Date: March 7, 2024
Time: 1:00 PM – 2:30 PM ET
FDA Websites of Interest
- FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)
- Transition to Electronic Export Documents – Letter to Industry (Medical Device)
- Importation Program under Section 804 of the FD&C Act
- FDA Elevates Office of Strategic Partnerships and Technology Innovation to Super Office in CDRH
- FDA Facilitates Broader Adoption of Vaporized Hydrogen Peroxide for Medical Device Sterilization